Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
Summary
This study will look at whether an investigational drug, called Ampreloxetine, works and how safe it is when taken over several months to treat symptomatic Neurogenic orthostatic hypotension in people with multiple system atrophy (MSA). It will also look at the effects of Ampreloxetine on general well-being and if it can improve symptoms of Neurogenic orthostatic hypotension.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 30 to 110
Inclusion criteria:
• Are at least 30 years of age
• Have symptoms related to Neurogenic orthostatic hypotension
• Have MSA
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Rasha Hamzeh autonomic.research@ucalgary.ca
Principal investigator:
Satish Raj
Clinical trial:
Yes
REB-ID:
REB23-0953